

***Pseudomonas aeruginosa* IgG ELISA Kit**

Quantitative test for serum *Ps. aeruginosa* IgG antibodies

Product code GD 07

96 tests

For *in vitro* diagnostic use



140610

1. Intended use

The *Ps. aeruginosa* IgG kit is a rapid ELISA method for the detection of antibodies to *Ps. aeruginosa*. Measurement of *Ps. aeruginosa* IgG in patients with cystic fibrosis and burn injuries may be used to monitor immune response to infection. Results are unaffected by antibiotics. The components of the kit are for *in vitro* diagnostic use only.

2. Explanation of the Test

Many hospitalised patients, particularly those with cystic fibrosis (CF) or severe burns, are prone to *Ps. aeruginosa* infection. *Ps. aeruginosa* may be difficult to eradicate and can be particularly virulent in CF patients. Regular monitoring of a patient's *Ps. aeruginosa* IgG status can be helpful in dealing with early onset of infection. Some studies have suggested that CF patients should be monitored from an early age to establish pre-infection baseline values.

Levels of serum antibodies to *Ps. aeruginosa* are low in the general population but rise rapidly during *Ps. aeruginosa* infection. The *Ps. aeruginosa* IgG ELISA kit permits quantitative determinations of *Ps. aeruginosa* IgG activity and is of value in monitoring patient responses to infection and therapy.

3. Principle of the test

Diluted serum samples are incubated with partially purified *Ps. aeruginosa* lipopolysaccharides immobilised on microtitre wells. After washing away unbound serum components, rabbit anti-human IgG conjugated to horseradish peroxidase is added to the wells and this binds to surface-bound antibodies in the second incubation. Unbound conjugate is removed by washing, and a solution containing 3,3',5,5'-tetramethylbenzidine (TMB) and enzyme substrate is added to trace specific antibody binding. Addition of Stop Solution terminates the reaction and provides the appropriate pH for colour development. The optical densities of the standards, control and samples are measured using a microplate reader at 450nm.

4. Materials included in the kit

- **Microplate:** 96 wells in 12 X 8 break-apart strips, pre-coated with *Ps. aeruginosa* lipopolysaccharides, with holder in a foil bag with desiccant
- **Reagent 1: Sample Diluent** 150mM Tris-buffered saline, pH 7.2 with antimicrobial agent, 10ml, (blue), concentrate (x15)
- **Reagent 2: Wash Buffer** 100mM Tris-buffered saline with detergent, pH 7.2, 100 ml, **concentrate** (x10)
- **Reagent 3: Conjugate** rabbit anti-human IgG conjugated to horseradish peroxidase in protein stabilising solution and antimicrobial agent, 12 ml, (red), ready to use
- **Reagent 4: TMB Substrate** aqueous solution of TMB and hydrogen peroxide, 12 ml, ready to use
- **Reagent 5: Stop Solution** 0.25M sulphuric acid, 12 ml, ready to use
- **Standards:** 0, 6.25, 12.5, 25, 50 & 100 U/ml, 1ml of 10mM Tris-buffered saline containing human serum IgG antibodies to *Ps. aeruginosa*, ready to use
- **Positive Control:** 1ml of 10mM Tris-buffered saline containing human serum antibodies to *Ps. aeruginosa* ready to use
- **Instructions for use**

5. Other equipment required

1. Test tubes for dilution • graduated cylinder for preparing wash buffer • precision pipettes and disposable tips to deliver 10µl, 100µl, 1ml • EIA microplate washer or multi-channel pipette or wash bottle • distilled or de-ionised water • absorbent paper • EIA microplate reader with 450nm and optional 620nm reference filter. Alternatively, a suitable automated system may be used.
2. Instrumentation, whether manual or automated, should meet the following criteria: pipettes with better than 3% imprecision with no carry over between pipetting steps; microplate washers should remove 99% of fluid; automated machines should minimise time between washing and adding the next reagent.

6. Precautions

6.1 Safety Precautions

1. All reagents in this kit are for *in vitro* diagnostic use only.
2. Only experienced laboratory personnel should use this test. The test protocol must be followed strictly.
3. All human source material used in the preparation of standards and control for this product have been tested and found negative for antibodies to HIV, HbsAg and HCV. No test method, however, can offer complete assurance that infectious agents are absent. Therefore, all reagents containing human material should be handled as if potentially infectious. Operators should wear gloves and protective clothing when handling any patient sera or serum based products.
4. Reagents of this kit contain antimicrobial agents and the TMB Substrate solution contains 3,3',5,5'-tetramethylbenzidine. Avoid contact with the skin and eyes. Rinse immediately with plenty of water if any contact occurs.
5. The Stop Solution contains 0.25M sulphuric acid. Avoid contact with skin and eyes. Rinse immediately with plenty of water if contact occurs.
6. Any liquid that has been brought into contact with potentially infectious material has to be discarded in a container with a disinfectant. Disposal must be performed in accordance with local legislation.

6.2 Technical Precautions

1. Strips and solutions should not be used if the foil bag is damaged or liquids have leaked.
2. Allow all reagents and the microplate to reach room temperature before use. Ensure that the microplate foil bag containing any unused strips is well sealed and contains the desiccant to avoid moisture. Store at 2 – 8°C after use.
3. The sample diluent X15 concentrate contains 0.09% sodium azide as preservative. Prepare sufficient working strength diluent for the assay run. However, if the working strength diluent is to be stored for more than 1 week, add sodium azide (0.9g/L). Store unused sample diluent concentrate and dilute sample diluent at 2 – 8°C.
4. Include the Positive Control in every test run to monitor for reagent stability and correct assay performance.
5. Strictly observe the indicated incubation times and temperature.
6. When automating, consider excess volumes required for setting up the instrument and dead volume of robot pipette
7. Ensure that no cross-contamination occurs between wells. Keep all pipettes and other equipment used for Conjugate completely separate from the TMB Substrate reagent.
8. When pipetting Conjugate or TMB Substrate, aliquots for the required numbers of wells should be taken to avoid multiple entry of pipette tips into the reagent bottles. Never pour unused reagents back into the original bottles.
9. Do not allow microwells to dry between incubation steps.
10. Strictly follow the described wash procedure. Insufficient washing may cause high background signal.
11. Avoid direct sunlight and exposure to heat sources during all incubation steps.
12. Replace colour-coded caps on their correct vials to avoid cross-contamination
13. It is important to dispense all samples and the positive control into the wells without delay. Therefore ensure that all samples are ready to dispense.

7. Shelf life and storage conditions

On arrival, store the kit at 2 – 8°C. Once opened the kit is stable for 3 months (or until its expiry date if less than 3 months). Do not use kits beyond their expiry date. Do not freeze any kit component. The diluted Wash Buffer and diluent (see Technical Precautions) have a shelf life of 3 months if stored in a closed bottle at 2 – 8°C.

8. Specimen collection and storage

Serum and plasma samples may be used and should be stored at -20°C for long-term storage. Frozen samples must be mixed well after thawing and prior to testing. Repeated freezing and thawing can affect results. Addition of preservatives to the serum sample may adversely affect the results. Microbially contaminated, heat-treated or specimens containing particulate matter should not be used. Grossly haemolysed, icteric or lipaemic specimens should be avoided.

9. Preparation of reagents

1. Dilute the Sample Diluent (**Reagent 1**) 1:14 in distilled water to make sufficient buffer for the assay run e.g. add 10ml sample diluent concentrate to 140 ml water.
2. Dilute the Wash Buffer (**Reagent 2**) 1: 9 in distilled water to make sufficient buffer for the assay run e.g. add 50ml wash buffer concentrate to 450ml water.

10. Assay Procedure

1. Dilute patient samples 1:100 in diluted Sample Diluent (e.g. 10µl serum plus 1ml diluent).
2. Assemble the number of strips required for the assay.
3. Dispense 100 µl of each Standard, the Positive Control and the diluted patient samples into appropriate wells.
4. Incubate for **30** minutes at room temperature.
5. After 30 minutes, decant or aspirate the well contents and wash the wells 3 times using automated washing or the manual wash procedure (see below). Careful washing is the key to good results. **Do not allow the wells to dry out.**

Manual Wash Procedure:

Empty the wells by inversion. Using a multi-channel pipette or wash bottle, fill the wells with wash buffer. Empty by inversion and blot the wells on absorbent paper. Repeat this wash process 2 more times.

6. Dispense 100µl of Conjugate (**Reagent 3**) into each well. Incubate the wells for **30** minutes at room temperature.
7. After 30 minutes, discard the well contents and carefully wash the wells 4 times with Wash Buffer. Ensure that the wells are empty but do not allow to dry out.
8. Using a repeating dispenser, rapidly dispense 100µl of TMB Substrate (**Reagent 4**) into each well. Incubate the plate for **10** minutes.
9. Add 100µl of Stop Solution (**Reagent 5**) to each well. To allow equal reaction times, the Stop Solution should be added to the wells in the same order as the TMB Substrate.
10. Read the optical density (OD) of each well at 450nm in a microplate reader within 10 minutes. A 620nm filter may be used as a reference wavelength.

11. Quality control

Quality control data is supplied on the lot-specific QC certificate included in the kit.

The positive control is intended to monitor for substantial reagent failure.

Any well positive by spectrophotometer but without visible colour should be cleaned on the underside and re-read. If OD values below zero are observed, the wavelengths used should be verified, the reader re-blanked to air and the measurements repeated.

12. Interpretation of Results

Plot the optical density of each standard against its concentration and draw the best-fit curve through the points. Read the unknowns off this curve.

We have established that 95% of healthy subjects have values less than 6U/ml. However, each laboratory is advised to establish its own normal range. Values above 100 U/ml should be re-assayed at a higher dilution.

13. Limitations of the Procedure

For diagnostic purposes, *Ps. aeruginosa* IgG ELISA results should be used in conjunction with other test results and overall clinical presentation.

14. Performance Characteristics

Assay Sensitivity

Calculated from the variance of the zero standard = 0.75 U/ml

15. Reproducibility

Within Assay Imprecision

Mean U/ml	SD	n	CV%	
22.0		1.4	12	6.3
78.4		6.6	12	8.4

Between Assay Imprecision <12%

Method Summary

- Dilute sera 1:100 with sample diluent (**Reagent 1**)
- Dispense 100µl of each standard, the positive control and diluted sample into microplate wells
- Incubate at room temperature **30** minutes.
- *Wash the wells three times.*
- Dispense 100µl of Conjugate (**Reagent 3**) into each well.
- Incubate at room temperature **30** minutes.
- *Wash the wells four times.*
- Add 100µl of TMB Substrate (**Reagent 4**) to each well
- Incubate at room temperature for **10** minutes
- Add 100µl Stop Solution (**Reagent 5**) to each well
- Read OD at 450nm within 10 minutes

Further reading

Pedersen, SS et al (1990)

IgA and IgG responses to alginates from *Ps. aeruginosa* in patients with cystic fibrosis

J Clin Microbiol 28(4): 747-755

Brett, MM et al (1990)

Serum IgA against *Ps. aeruginosa* in cystic fibrosis

Arch Dis Child 65 (3): 259-263

Schaad, UB et al (1990)

Serotype specific IgG antibodies to LPS of *Ps. aeruginosa* in cystic fibrosis: Correlation to disease, sub-class distribution and experimental protective capacity.

Paed Res 27(5) : 508-513

Pressler, T et al (1990)

IgG subclass antibodies to *Ps. aeruginosa* in sera from patients with chronic *Ps A* infection investigated by ELISA.

Clin Exp Immunol 81(3) 428-434

Johansen, HK and Holby, N (1992)

Local IgA and IgG response to intr-tracheal Immunisation with *Ps. aeruginosa* antigens. *APMIS* 100(1): 87 - 90

Gordon, SM et al (1992)

IgG antibodies in early *Ps. aeruginosa* infection in cystic fibrosis.

Arch Dis Child 67(6) 737 - 740

Bantroch, S. et al (1994)

Appropriate coating methods and other conditions for ELISA of smooth, rough and neutral LPS of *Pseudomonas Aeruginosa*. *Clin Diagn Lab Immunol (USA)*, 1(1), 55 - 62.